Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

More documents

Recommendations

Info

Contents 01 Consolidated Financial Highlights 02 To Our Shareholders 06 Achieving Customer Satisfaction 08 Research and Development 13 Review of Operations 13 Prescription Pharmaceuticals 15 Consumer Health Care Products 16 Other Operations 17 Reinforcing Our Relationship with Stakeholders 18 Corporate History 19 Financial Section 40 Japan and Overseas Operations 42 Major Products 43 Board of Directors, Corporate Officers, and Corporate Auditors 44 Corporate Information Profile Eisai Annual Report 2001 Eisai Co., Ltd., seeks to meet the diverse health care needs of patients and their families as a human health care company by working to develop superior pharmaceutical products in response to unmet medical needs while observing the highest legal and ethical standards. Forward-Looking Statements Statements in this annual report, other than those of historical fact, are forward-looking statements about the future performance of Eisai that are based on management’s assumptions and beliefs in light of information currently available, and involve both known and unknown risks and uncertainties. Actual events and results may differ materially from those anticipated in these statements.
CONSOLIDATED FINANCIAL HIGHLIGHTS Eisai Co., Ltd. and Consolidated Subsidiaries Years ended March 31 2001 2000 Millions of yen 1999 1998 1997 Net sales ¥361,712 ¥302,470 ¥284,860 ¥301,760 ¥281,561 Operating income 58,968 37,133 38,613 47,508 50,362 Net income 23,323 11,275 15,878 19,794 19,445 Research and development (R&D) expenses 49,614 46,704 43,698 45,139 38,348 Total shareholders’ equity 345,896 329,386 308,567 299,214 254,391 Total assets 549,444 485,674 463,384 453,050 456,618 Ratio of R&D expenses to net sales (%) 13.7 15.4 15.3 14.9 13.6 Return on equity ratio (%) 6.9 3.5 5.2 7.2 8.1 Shareholders’ equity ratio (%) 63.0 67.8 66.6 66.0 55.7 Net income per share ¥78.68 ¥38.04 ¥53.57 ¥69.98 ¥71.00 Diluted net income per share 77.91 37.70 53.06 67.08 66.86 Cash dividends per share 23.00 21.50 21.50 21.50 18.00 Note: Net income per share and diluted net income per share are computed based on the weighted average number of shares of common stock outstanding after retroactive adjustment for subsequent stock splits. (Millions of yen) 400,000 320,000 240,000 160,000 80,000 0 Net Sales 281,561 301,760 284,860 302,470 361,712 ’97 ’98 ’99 ’00 ’01 (Millions of yen) 25,000 20,000 15,000 10,000 5,000 0 Net Income 19,445 19,794 15,878 11,275 23,323 ’97 ’98 ’99 ’00 ’01 Eisai Annual Report 2001 Yen Total Assets / Equity Ratio (Millions of yen) 600,000 480,000 360,000 240,000 120,000 0 456,618 453,050 463,384 485,674 549,444 (%) 75 60 45 30 15 ’97 ’98 ’99 ’00 ’01 0 1
Page 1: Human Health Care The script for ou
Page 5 and 6: In Japan, we are proceeding with de
Page 7 and 8: Fiscal 2001 marks the conclusion of
Page 9 and 10: humanity-based sales activities the
Page 11 and 12: Selected Research Candidates (As of
Page 13 and 14: working together to develop antican
Page 15 and 16: REVIEW OF OPERATIONS PHARMACEUTICAL
Page 17 and 18: Consumer Health Care Products The c
Page 19 and 20: REINFORCING OUR RELATIONSHIP WITH S
Page 21 and 22: FINANCIAL SECTION Contents 20 Finan
Page 23: Net Income Current income taxes for
Page 26 and 27: 24 CONSOLIDATED FINANCIAL STATEMENT
Page 28 and 29: 26 Consolidated Statements of Incom
Page 30 and 31: 28 Consolidated Statements of Cash
Page 32 and 33: 30 (e) Property, plant and equipmen
Page 34 and 35: 32 Proceeds from sales of available
Page 36 and 37: 34 Note 7. Retirement and Pension P
Page 38 and 39: 36 III. Actual lease payments, Depr
Page 40 and 41: 38 Eisai Annual Report 2001 Million
Page 42 and 43: 40 JAPAN AND OVERSEAS OPERATIONS No
Page 44 and 45: 42 MAJOR PRODUCTS Prescription Phar
Page 46 and 47: 44 CORPORATE INFORMATION (As of Mar

Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?